Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 76 Neoplasms 16 Prostatic Neoplasms, Castration-Resistant 14 Neoplasm Metastasis 9 Breast Neoplasms 9 Metastatic Castration Resistant Prostate Cancer 8 Prostate Cancer Metastatic 5 Metastatic Castration-Resistant Prostate Cancer 5 Colorectal Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Metastatic Castration-resistant Prostate Cancer 3 Melanoma 3 Bulbo-Spinal Atrophy, X-Linked 3 mCRPC 2 Recurrence 2 Pancreatic Neoplasms 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castrate-Resistant Prostate Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumours 1 Seizures 1

Interventions

Cannabidiol 5 Everolimus 2 enzalutamide 1 Temozolomide 1 Standard of Care 1 Solutions 1 Lenalidomide 1 Drug Therapy 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Seizures × enzalutamide × Clear all

NCT01977651 2024-12-06

UPWARD

Astellas Pharma Inc

Phase 4 Completed

424 enrolled 10 charts

Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡